131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA
131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA
批准号:
6274061
负责人:
MANSOOR N SALEH
金额:
$2.59万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-01-26 至 1998-11-30
中文摘要
这是I-131标记的放射性抗B1的II期试验
用于治疗低度恶性淋巴瘤的单抗以及
转化的淋巴瘤。先前治疗失败的患者通常不会
有大量的选择,通常有较差的总体结果。这个
放射性标记抗-B1的I期试验证明了
提供85cGy全身辐射,具有适度的可逆毒性
与难治性低血压患者的显著反应相关
恶性淋巴瘤。目前的研究着眼于85cgy全身的剂量。
难治性低度淋巴瘤或转化性淋巴瘤的放射治疗。
英文摘要
This is a phase II trial of the I-131 labeled radioactive anti-B1
monoclonal antibody for the treatment of low grade lymphoma, as well as
transformed lymphoma. Patients who failed prior therapy generally do not
have substantial options, and in general have por overall outcome. The
phase I trial of the radiolabeled anti-B1 demonstrated the ability to
deliver 85 cGy whole body radiation with modest reversible toxicity and
was associated with significant responses in patients with refractory low
grade lymphoma. The current study looks at the dose of 85 cGy whole body
radiotherapy in refractory low grade lymphoma or transformed lymphoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
-
批准号:6565396
-
项目类别:
-
资助金额:$17.53万
-
财政年份:2001
-
负责人:MANSOOR N SALEH
-
依托单位:
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
-
批准号:6565387
-
项目类别:
-
资助金额:$17.53万
-
财政年份:2001
-
负责人:MANSOOR N SALEH
-
依托单位:
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
-
批准号:6410712
-
项目类别:
-
资助金额:$17.53万
-
财政年份:2000
-
负责人:MANSOOR N SALEH
-
依托单位:
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
-
批准号:6410703
-
项目类别:
-
资助金额:$17.53万
-
财政年份:2000
-
负责人:MANSOOR N SALEH
-
依托单位:
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
-
批准号:6302997
-
项目类别:
-
资助金额:$2.95万
-
财政年份:1999
-
负责人:MANSOOR N SALEH
-
依托单位:
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
-
批准号:6303008
-
项目类别:
-
资助金额:$2.95万
-
财政年份:1999
-
负责人:MANSOOR N SALEH
-
依托单位:
BR96 DOXORUBICIN CONJUGATE VS DOXORUBICIN IN METASTATIC BREAST CANCER
-
批准号:6274063
-
项目类别:
-
资助金额:$2.59万
-
财政年份:1998
-
负责人:MANSOOR N SALEH
-
依托单位:
ORAL BCX 34 IN T CELL MALIGANCIES
-
批准号:6112812
-
项目类别:
-
资助金额:$2.95万
-
财政年份:1998
-
负责人:MANSOOR N SALEH
-
依托单位:
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
-
批准号:6263448
-
项目类别:
-
资助金额:$2.95万
-
财政年份:1998
-
负责人:MANSOOR N SALEH
-
依托单位:
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
-
批准号:6263459
-
项目类别:
-
资助金额:$2.95万
-
财政年份:1998
-
负责人:MANSOOR N SALEH
-
依托单位:
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM
-
批准号:2896329
-
项目类别:
-
资助金额:$31.56万
-
财政年份:1997
-
负责人:MANSOOR N SALEH
-
依托单位:
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM
-
批准号:2733417
-
项目类别:
-
资助金额:$30.89万
-
财政年份:1997
-
负责人:MANSOOR N SALEH
-
依托单位:
BR96-DOXORUBICIN CONJUGATE IN METASTATIC BREAST CANCER
-
批准号:6244047
-
项目类别:
-
资助金额:$2.46万
-
财政年份:1997
-
负责人:MANSOOR N SALEH
-
依托单位:
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM
-
批准号:2541318
-
项目类别:
-
资助金额:$30.24万
-
财政年份:1997
-
负责人:MANSOOR N SALEH
-
依托单位:
131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA
-
批准号:6244045
-
项目类别:
-
资助金额:$2.46万
-
财政年份:1997
-
负责人:MANSOOR N SALEH
-
依托单位:
GENERATION AND CLINICAL USE OF HUMAN ANTIID ANTIBODIES
-
批准号:2100171
-
项目类别:
-
资助金额:$16.5万
-
财政年份:1994
-
负责人:MANSOOR N SALEH
-
依托单位:
GENERATION AND CLINICAL USE OF HUMAN ANTIID ANTIBODIES
-
批准号:2100173
-
项目类别:
-
资助金额:$17.63万
-
财政年份:1994
-
负责人:MANSOOR N SALEH
-
依托单位:
GENERATION AND CLINICAL USE OF HUMAN ANTIID ANTIBODIES
-
批准号:2100172
-
项目类别:
-
资助金额:$16.92万
-
财政年份:1994
-
负责人:MANSOOR N SALEH
-
依托单位:
FC-RECEPTOR MEDIATED CELL-CELL INTERACTION IN ITP
-
批准号:3471403
-
项目类别:
-
资助金额:$8.65万
-
财政年份:1988
-
负责人:MANSOOR N SALEH
-
依托单位:
FC-RECEPTOR MEDIATED CELL-CELL INTERACTION IN ITP
-
批准号:3471406
-
项目类别:
-
资助金额:$10.42万
-
财政年份:1988
-
负责人:MANSOOR N SALEH
-
依托单位:
海外基金